argos therapeutics appoints dr ralph snyderman and irackly mtibelishvily to the company’s board of directors nasdaqargs english français register sign in argos therapeutics appoints dr ralph snyderman and irackly mtibelishvily to the company’s board of directors  dr snyderman widely considered the ‘father of personalized medicine’  december    et  source argos therapeutics inc durham nc dec   globe newswire  argos therapeutics inc nasdaqargs “argos” an immunooncology company focused on the development and commercialization of individualized immunotherapies based on the arcelis® precision immunotherapy technology platform today announced the appointment of ralph snyderman md and irackly mtibelishvily llm to the companys board of directors “it is a privilege to welcome a pair of profoundly accomplished professionals to the argos board of directors who offer renowned expertise in each of their respective fields” said jeff abbey president and ceo of argos “dr snyderman is widely referred to as the ‘father of personalized medicine’ and his experience running the duke university health system as well as his senior leadership roles at genentech will help guide us as we advance our individualized immunotherapy through the final stages of clinical development assess indication expansion and approach our goal of becoming a fullyintegrated commercial company in addition irackly mtibelishvily is globally recognized as one of the most experienced international investment bankers and will advise on important corporate finance and other strategic activities in the years ahead” dr snyderman is chancellor emeritus at duke university james b duke professor of medicine and director of the center for research on personalized health care  he served as chancellor for health affairs and dean of the duke university school of medicine from  to   during this time he oversaw the development of the duke university health system and served as its first president and chief executive officer dr snyderman has played a leading role in the conception and development of personalized health care an evolving model of national health care delivery  previously dr snyderman served as senior vice president for medical research and development at genentech inc the pioneering biomedical technology firm  he has played a leadership role in important national organizations such as the association of american physicians the national academy of medicine and association of american medical colleges dr snyderman earned a doctor of medicine degree from suny downstate medical center mr mtibelishvily is currently managing director and chairman of corporate and investment banking in central and eastern europe the middle east and africa for citigroup where he has served in various roles for nearly two decades a specialist in corporate finance capital markets securities and mergers and acquisitions mr mtibelishvily also has experience working with the multinational law firm clifford chance llp he earned a master of international legal studies degree from the moscow state institute of international relations and a master of laws degree from the university of virginia law school dr snyderman and mr mtibelishvily will replace vacating argos directors philippe van holle mba and andrei petrov phd “on behalf of the management team board of directors and shareholders i would like to thank philippe and andrei for their dedication and support over the last several years” said hubert birner phd chairman of the argos board of directors “they each have played an instrumental role in the growth and development of argos” about the arcelis® technology platformarcelis® is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient’s individual disease it is designed to overcome immunosuppression by producing a specifically targeted durable memory tcell response without adjuvants that may be associated with toxicity the technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies the arcelis® process uses only a small disease sample or biopsy as the source of diseasespecific antigens and the patient’s own dendritic cells which are optimized from cells collected by a single leukapheresis procedure the proprietary process uses rna isolated from the patients disease sample to program dendritic cells to target diseasespecific antigens these activated antigenloaded dendritic cells are then formulated with the patient’s plasma and administered via intradermal injection as an individualized immunotherapy about argos therapeuticsargos therapeutics is an immunooncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its arcelis® technology platform argos most advanced product candidate ags is being evaluated in the pivotal adapt phase  clinical trial for the treatment of metastatic renal cell carcinoma mrcc  in addition ags is being studied in phase  investigatorinitiated clinical trials as neoadjuvant therapy for renal cell carcinoma rcc and for the treatment of nonsmall cell lung cancer nsclc argos is also developing a separate arcelis®based product candidate ags for the treatment of human immunodeficiency virus hiv which is currently being evaluated in an investigatorinitiated phase  clinical trial aimed at hiv eradication in adult patients forward looking statementsany statements in this press release about argos’ future expectations plans and prospects including statements about the expected and potential future closings of the private placement argos’ financial prospects anticipated use of proceeds future operations and sufficiency of funds for future operations clinical development of argos’ product candidates expectations regarding future clinical trials and future expectations and plans and prospects for argos and other statements containing the words believes anticipates estimates expects intends plans predicts projects targets “may” potential will would could should continue and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of   actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including whether argos cash resources will be sufficient to fund its continuing operations for the periods anticipated whether results obtained in clinical trials will be indicative of results obtained in future clinical trials whether argos product candidates will advance through the clinical trial process on a timely basis whether the results of such trials will warrant submission for approval from the united states food and drug administration or equivalent foreign regulatory agencies whether argos product candidates will receive approval from regulatory agencies on a timely basis or at all whether if product candidates obtain approval they will be successfully distributed and marketed and other factors discussed in the risk factors section of argos’ form q for the quarter ended september   which is on file with the sec and in other filings argos makes with the sec from time to time in addition the forwardlooking statements included in this press release represent argos’ views as of the date hereof argos anticipates that subsequent events and developments will cause argos’ views to change however while argos may elect to update these forwardlooking statements at some point in the future argos specifically disclaims any obligation to do so these forwardlooking statements should not be relied upon as representing argos’ views as of any date subsequent to the date hereofmedia contact adam daley berry  company public relations  adaleyberryprcom investor contact john menditto argos therapeutics inc  jmendittoargostherapeuticscom related articles other press releases by argos therapeutics inc argos reports immunogenicity results of ags in hiv program july    argos therapeutics announces closing of  million secured convertible note financing june    argos therapeutics announces  secured convertible note financing june    argos provides update on its adapt trial following meeting with fda may    argos reports interim results of the adapt trial and provides perspective on decision to continue the trial april     other news releases in directors and officers in the last  days profile argos therapeutics inc   subscribe via rss  subscribe via atom  javascript durham north carolina united states contact data media contact adam daley berry  company public relations  adaleyberryprcom investor contact john menditto argos therapeutics inc  jmendittoargostherapeuticscom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files argos therapeutics inc logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved argos therapeutics appoints dr ralph snyderman and irackly mtibelishvily to the companys board of directors  pg  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street argos therapeutics appoints dr ralph snyderman and irackly mtibelishvily to the companys board of directors globenewswire dec    am est mr mtibelishvily is currently managing director and chairman of corporate and investment banking in central and eastern europe the middle east and africa for citigroup where he has served in various roles for nearly two decades a specialist in corporate finance capital markets securities and mergers and acquisitions mr mtibelishvily also has experience working with the multinational law firm clifford chance llp he earned a master of international legal studies degree from the moscow state institute of international relations and a master of laws degree from the university of virginia law school dr snyderman and mr mtibelishvily will replace vacating argos directors philippe van holle mba and andrei petrov phd on behalf of the management team board of directors and shareholders i would like to thank philippe and andrei for their dedication and support over the last several years said hubert birner phd chairman of the argos board of directors they each have played an instrumental role in the growth and development of argos about the arcelis® technology platform arcelis® is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patients individual disease it is designed to overcome immunosuppression by producing a specifically targeted durable memory tcell response without adjuvants that may be associated with toxicity the technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies the arcelis® process uses only a small disease sample or biopsy as the source of diseasespecific antigens and the patients own dendritic cells which are optimized from cells collected by a single leukapheresis procedure the proprietary process uses rna isolated from the patients disease sample to program dendritic cells to target diseasespecific antigens these activated antigenloaded dendritic cells are then formulated with the patients plasma and administered via intradermal injection as an individualized immunotherapy about argos therapeuticsargos therapeutics is an immunooncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its arcelis® technology platform argos most advanced product candidate ags is being evaluated in the pivotal adapt phase  clinical trial for the treatment of metastatic renal cell carcinoma mrcc  in addition ags is being studied in phase  investigatorinitiated clinical trials as neoadjuvant therapy for renal cell carcinoma rcc and for the treatment of nonsmall cell lung cancer nsclc argos is also developing a separate arcelis®based product candidate ags for the treatment of human immunodeficiency virus hiv which is currently being evaluated in an investigatorinitiated phase  clinical trial aimed at hiv eradication in adult patients forward looking statementsany statements in this press release about argos future expectations plans and prospects including statements about the expected and potential future closings of the private placement argos financial prospects anticipated use of proceeds future operations and sufficiency of funds for future operations clinical development of argos product candidates expectations regarding future clinical trials and future expectations and plans and prospects for argos and other statements containing the words believes anticipates estimates expects intends plans predicts projects targets may potential will would could should continue and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of   actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including whether argos cash resources will be sufficient to fund its continuing operations for the periods anticipated whether results obtained in clinical trials will be indicative of results obtained in future clinical trials whether argos product candidates will advance through the clinical trial process on a timely basis whether the results of such trials will warrant submission for approval from the united states food and drug administration or equivalent foreign regulatory agencies whether argos product candidates will receive approval from regulatory agencies on a timely basis or at all whether if product candidates obtain approval they will be successfully distributed and marketed and other factors discussed in the risk factors section of argos form q for the quarter ended september   which is on file with the sec and in other filings argos makes with the sec from time to time in addition the forwardlooking statements included in this press release represent argos views as of the date hereof argos anticipates that subsequent events and developments will cause argos views to change however while argos may elect to update these forwardlooking statements at some point in the future argos specifically disclaims any obligation to do so these forwardlooking statements should not be relied upon as representing argos views as of any date subsequent to the date hereof media contactadam daley berry  company public relationsadaleyberryprcominvestor contactjohn mendittoargos therapeutics incjmendittoargostherapeuticscom if you liked this article you might like sp  trades lower as fed signals move on rates fairly soon the sp  holds lower on wednesday after the federal reserve signaled comfort in moving to higher interest rate levels fairly soon keris alison lahiff feb    pm est dow turns positive in wishywashy trading ahead of fed minutes stocks turn mixed on wednesday morning as investors await more clarity on interest rates from the federal reserve keris alison lahiff feb    am est argos therapeutics tanks on committee suggestion to stop carcinoma drug study argos tanks after committee recommends the discontinuation of the companys carcinoma treatment study tony owusu feb    am est stock futures waver as wall street awaits clarity from the fed stock futures waver on wednesday morning as investors seek more clarity on interest rates from the federal reserve keris alison lahiff feb    am est trending facebook just gave a glimpse into one of its big new business areas tesla headlines this lineup of  amazing new cars for  records all around for wall street after fed hints at balance sheet unwind soon apples iphone  is coming and it could be in your hands very soon what could president trump actually do to amazon and jeff bezos advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers args irackly mtibelishvily insider trades for argos therapeutics inc bulletin investor alert tokyo markets close in currencies europe markets london markets expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close argos therapeutics inc nasdaq args go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus argos therapeutics inc after hours  quotes are delayed by  min jul    pm args quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   insider activity individual irackly mtibelishvily mr irackly mtibelishvily is on the board of directors at argos therapeutics inc he received his graduate degree from mgimo university and a graduate degree from the university of virginia school of law transactions date shares transaction value     award at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr jeffrey d abbey president chief executive officer  director dr richard d katz chief financial officer  vice president dr charles a nicolette chief scientific officer mr irackly mtibelishvily director mr igor krol director ms lori r harrelson principal accounting officer  vpfinance mr john d menditto vpinvestor relations  corporate communications dr hubert birner chairman dr sander j van deventer independent director mr robert f carey independent director log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pscaramucci on washington back stabbers ‘i’m more of a frontstabbing person’ pfacebook keeps warning about growth but growth doesn’t stop pfacebook heads toward  billion market cap after earnings pfoxconn pledges to build  billion stateoftheart electronics plant in wisconsin pgraham says trump is showing weakness in unilateral public spat with sessions pfacebook hits  billion users earnings beat boosts stock live blog recap pnew rules for ftse russell index provider to exclude snap others from benchmarks pthe nintendo switch’s sellout launch in many charts p coworkers you should avoid like the plague in meetings pcommunity health systems shares fall after profit warning pwhat donald trump’s battle of wills with jeff sessions teaches you about a difficult boss pstock market ends at record on robust earnings as fed issues policy update ptrump puts his hands together for ‘the late great abraham lincoln’ pyear treasury yield falls the most in five weeks after fed statement pfor transgender americans workplace discrimination isn’t limited to the military pyour k match may have some strings attached pthis is the worst mistake people make at work pwhy equalweighted stockmarket indexes bounce back faster from bear markets pnutrisystem shares rally on betterthanexpected earnings pbuffalo wild wings drop  on high chicken wing costs loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  argos therapeutics appoints dr ralph snyderman and irackly mtibelishvily to the company’s board of directors  pt community skip to main content pt community registersign in search form search home news ptcurrent issue past issues masthead digital edition subscribe pt tv authors about contact us   ingrezza® valbenazine tablets‎ zurampic® lesinurad tabletsplease click for full prescribing information including boxed warning you are herehome argos therapeutics appoints dr ralph snyderman and irackly mtibelishvily to the company’s board of directors durham nc dec   globe newswire  argos therapeutics inc nasdaqargs “argos” an immunooncology company focused on the development and commercialization of individualized immunotherapies based on the arcelis® precision immunotherapy technology platform today announced the appointment of ralph snyderman md and irackly mtibelishvily llm to the companys board of directors “it is a privilege to welcome a pair of profoundly accomplished professionals to the argos board of directors who offer renowned expertise in each of their respective fields” said jeff abbey president and ceo of argos “dr snyderman is widely referred to as the ‘father of personalized medicine’ and his experience running the duke university health system as well as his senior leadership roles at genentech will help guide us as we advance our individualized immunotherapy through the final stages of clinical development assess indication expansion and approach our goal of becoming a fullyintegrated commercial company in addition irackly mtibelishvily is globally recognized as one of the most experienced international investment bankers and will advise on important corporate finance and other strategic activities in the years ahead” dr snyderman is chancellor emeritus at duke university james b duke professor of medicine and director of the center for research on personalized health care  he served as chancellor for health affairs and dean of the duke university school of medicine from  to   during this time he oversaw the development of the duke university health system and served as its first president and chief executive officer dr snyderman has played a leading role in the conception and development of personalized health care an evolving model of national health care delivery  previously dr snyderman served as senior vice president for medical research and development at genentech inc the pioneering biomedical technology firm  he has played a leadership role in important national organizations such as the association of american physicians the national academy of medicine and association of american medical colleges dr snyderman earned a doctor of medicine degree from suny downstate medical center mr mtibelishvily is currently managing director and chairman of corporate and investment banking in central and eastern europe the middle east and africa for citigroup where he has served in various roles for nearly two decades a specialist in corporate finance capital markets securities and mergers and acquisitions mr mtibelishvily also has experience working with the multinational law firm clifford chance llp he earned a master of international legal studies degree from the moscow state institute of international relations and a master of laws degree from the university of virginia law school dr snyderman and mr mtibelishvily will replace vacating argos directors philippe van holle mba and andrei petrov phd “on behalf of the management team board of directors and shareholders i would like to thank philippe and andrei for their dedication and support over the last several years” said hubert birner phd chairman of the argos board of directors “they each have played an instrumental role in the growth and development of argos” about the arcelis® technology platformarcelis® is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient’s individual disease it is designed to overcome immunosuppression by producing a specifically targeted durable memory tcell response without adjuvants that may be associated with toxicity the technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies the arcelis® process uses only a small disease sample or biopsy as the source of diseasespecific antigens and the patient’s own dendritic cells which are optimized from cells collected by a single leukapheresis procedure the proprietary process uses rna isolated from the patients disease sample to program dendritic cells to target diseasespecific antigens these activated antigenloaded dendritic cells are then formulated with the patient’s plasma and administered via intradermal injection as an individualized immunotherapy about argos therapeuticsargos therapeutics is an immunooncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its arcelis® technology platform argos most advanced product candidate ags is being evaluated in the pivotal adapt phase  clinical trial for the treatment of metastatic renal cell carcinoma mrcc  in addition ags is being studied in phase  investigatorinitiated clinical trials as neoadjuvant therapy for renal cell carcinoma rcc and for the treatment of nonsmall cell lung cancer nsclc argos is also developing a separate arcelis®based product candidate ags for the treatment of human immunodeficiency virus hiv which is currently being evaluated in an investigatorinitiated phase  clinical trial aimed at hiv eradication in adult patients forward looking statementsany statements in this press release about argos’ future expectations plans and prospects including statements about the expected and potential future closings of the private placement argos’ financial prospects anticipated use of proceeds future operations and sufficiency of funds for future operations clinical development of argos’ product candidates expectations regarding future clinical trials and future expectations and plans and prospects for argos and other statements containing the words believes anticipates estimates expects intends plans predicts projects targets “may” potential will would could should continue and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of   actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including whether argos cash resources will be sufficient to fund its continuing operations for the periods anticipated whether results obtained in clinical trials will be indicative of results obtained in future clinical trials whether argos product candidates will advance through the clinical trial process on a timely basis whether the results of such trials will warrant submission for approval from the united states food and drug administration or equivalent foreign regulatory agencies whether argos product candidates will receive approval from regulatory agencies on a timely basis or at all whether if product candidates obtain approval they will be successfully distributed and marketed and other factors discussed in the risk factors section of argos’ form q for the quarter ended september   which is on file with the sec and in other filings argos makes with the sec from time to time in addition the forwardlooking statements included in this press release represent argos’ views as of the date hereof argos anticipates that subsequent events and developments will cause argos’ views to change however while argos may elect to update these forwardlooking statements at some point in the future argos specifically disclaims any obligation to do so these forwardlooking statements should not be relied upon as representing argos’ views as of any date subsequent to the date hereofcontact media contact adam daley berry  company public relations  adaleyberryprcom investor contact john menditto argos therapeutics inc  jmendittoargostherapeuticscomtuesday december     stay in touch newsletters available pt and drug management daily news pt table of contents monthly contact us editorial j stephen mciver editoradvertising maureen dwyer liberti vice president group publisherproduction dawn flook director of production servicescirculation jackie ott circulation managerwebmaster webmaster industry announcements affimed presents data on firstinclass bcmatargeting immune cell engager afm at asco annual meeting  share buyback week  novartis drug tasigna receives eu approval for inclusion of treatmentfree remission tfr data in product label basilea announces presentation of interim phase a clinical data with anticancer drug candidate bal at asco meeting targovax presents further positive clinical data from tg phase iii trial at  asco annual meeting addex annual general meeting scheduled for  june  valneva to present at jefferies  global healthcare conference in new york targovax announces formal agenda for  capital markets updates in oslo and london lundbeck obtains rights to breakthrough research in alzheimer’s disease veloxis pharmaceuticals as announces agreement with chiesi farmaceutici spa to commercialize envarsus xr in china more from globe newswire current issue of pt july  user login username  password  create new account request new password argos therapeutics appoints dr ralph snyderman and irackly mtibelishvily to the company’s board of directors – pm nasdaqargos therapeutics appoints dr ralph linkedin macrolide monotherapy works in some type in your search and press enter nasdaq argos therapeutics appoints dr ralph snyderman and irackly mtibelishvily to the company’s board of directorsnasdaqnasdaq infectious diseases market newsargos therapeutics appoints dr ralph snyderman and irackly mtibelishvily to the company’s board of directors bynasdaq market newsdecember   facebook twitter linkedin linkedinshares durham nc dec   globe newswire  argos therapeutics inc nasdaqargs “argos” an immunooncology company focused on the development and commercialization of individualized immunotherapies based on the arcelis® precision immunotherapy technology platform today announced the appointment of ralph snyderman md and irackly mtibelishvily llm to the companys board of directors “it is a privilege to welcome a pair of profoundly accomplished professionals to the argos board of directors who offer renowned expertise in each of their respective fields” said jeff abbey president and ceo of argos “dr snyderman is widely referred to as the ‘father of personalized medicine’ and his experience running the duke university health system as well as his senior leadership roles at genentech will help guide us as we advance our individualized immunotherapy through the final stages of clinical development assess indication expansion and approach our goal of becoming a fullyintegrated commercial company in addition irackly mtibelishvily is globally recognized as one of the most experienced international investment bankers and will advise on important corporate finance and other strategic activities in the years ahead” dr snyderman is chancellor emeritus at duke university james b duke professor of medicine and director of the center for research on personalized health care  he served as chancellor for health affairs and dean of the duke university school of medicine from  to   during this time he oversaw the development of the duke university health system and served as its first president and chief executive officer dr snyderman has played a leading role in the conception and development of personalized health care an evolving model of national health care delivery  previously dr snyderman served as senior vice president for medical research and development at genentech inc the pioneering biomedical technology firm  he has played a leadership role in important national organizations such as the association of american physicians the national academy of medicine and association of american medical colleges dr snyderman earned a doctor of medicine degree from suny downstate medical center mr mtibelishvily is currently managing director and chairman of corporate and investment banking in central and eastern europe the middle east and africa for citigroup where he has served in various roles for nearly two decades a specialist in corporate finance capital markets securities and mergers and acquisitions mr mtibelishvily also has experience working with the multinational law firm clifford chance llp he earned a master of international legal studies degree from the moscow state institute of international relations and a master of laws degree from the university of virginia law school dr snyderman and mr mtibelishvily will replace vacating argos directors philippe van holle mba and andrei petrov phd “on behalf of the management team board of directors and shareholders i would like to thank philippe and andrei for their dedication and support over the last several years” said hubert birner phd chairman of the argos board of directors “they each have played an instrumental role in the growth and development of argos” about the arcelis® technology platformarcelis® is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient’s individual disease it is designed to overcome immunosuppression by producing a specifically targeted durable memory tcell response without adjuvants that may be associated with toxicity the technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies the arcelis® process uses only a small disease sample or biopsy as the source of diseasespecific antigens and the patient’s own dendritic cells which are optimized from cells collected by a single leukapheresis procedure the proprietary process uses rna isolated from the patients disease sample to program dendritic cells to target diseasespecific antigens these activated antigenloaded dendritic cells are then formulated with the patient’s plasma and administered via intradermal injection as an individualized immunotherapy about argos therapeuticsargos therapeutics is an immunooncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its arcelis® technology platform argos most advanced product candidate ags is being evaluated in the pivotal adapt phase  clinical trial for the treatment of metastatic renal cell carcinoma mrcc  in addition ags is being studied in phase  investigatorinitiated clinical trials as neoadjuvant therapy for renal cell carcinoma rcc and for the treatment of nonsmall cell lung cancer nsclc argos is also developing a separate arcelis®based product candidate ags for the treatment of human immunodeficiency virus hiv which is currently being evaluated in an investigatorinitiated phase  clinical trial aimed at hiv eradication in adult patients forward looking statementsany statements in this press release about argos’ future expectations plans and prospects including statements about the expected and potential future closings of the private placement argos’ financial prospects anticipated use of proceeds future operations and sufficiency of funds for future operations clinical development of argos’ product candidates expectations regarding future clinical trials and future expectations and plans and prospects for argos and other statements containing the words believes anticipates estimates expects intends plans predicts projects targets “may” potential will would could should continue and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of   actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including whether argos cash resources will be sufficient to fund its continuing operations for the periods anticipated whether results obtained in clinical trials will be indicative of results obtained in future clinical trials whether argos product candidates will advance through the clinical trial process on a timely basis whether the results of such trials will warrant submission for approval from the united states food and drug administration or equivalent foreign regulatory agencies whether argos product candidates will receive approval from regulatory agencies on a timely basis or at all whether if product candidates obtain approval they will be successfully distributed and marketed and other factors discussed in the risk factors section of argos’ form q for the quarter ended september   which is on file with the sec and in other filings argos makes with the sec from time to time in addition the forwardlooking statements included in this press release represent argos’ views as of the date hereof argos anticipates that subsequent events and developments will cause argos’ views to change however while argos may elect to update these forwardlooking statements at some point in the future argos specifically disclaims any obligation to do so these forwardlooking statements should not be relied upon as representing argos’ views as of any date subsequent to the date hereofcontact media contact adam daley berry  company public relations  adaleyberryprcom investor contact john menditto argos therapeutics inc  jmendittoargostherapeuticscomfacebook twitter linkedin linkedinshares nasdaq market newsclick here to email authornext storymacrolide monotherapy works in some ntm lung diseaseprev storyfda affirms bladder cancer warning with diabetes drugsubscribe to pmfollow usexperts on callrick ratliffemrehr connectionsjeffrey d erblife sciences medical strategy don feilerbrand engagementerik daltonhcp engagementrichard meyerdtc marketingjohn weinman phdhealth psychologychris dowdpatient loyaltyamy groggrare disease  orphan drug commercialization bud bilanichsuccess coachjessica brueggemanpatientprovider dialoguebrenda snowauthentic patient voice get in touch with pm experts on calladsyou may also likenasdaqnasdaq mental health market newsdoctors administrative solutions acquires conxit technology group forms national health it  management solutions firm das healthtampa fla jan   globe newswire  united by a common business culture nasdaq market newsjanuary  nasdaqnasdaq mental health market newslightlake therapeutics inc announces collaboration with nida and the perelman school of medicine at the university of pennsylvanianew york dec   globe newswire  lightlake therapeutics inc “lightlake” otcqblltp a nasdaq market newsjanuary  nasdaqnasdaq mental health market newscaresource foundation awards  million to ohio nonprofit organizations in dayton ohio dec   globe newswire  the caresource foundation has announced the nasdaq market newsjanuary   argos therapeutics inc  args company news at ally invest quotes snapshot  argsargos therapeutics inc argsnasdaqset alertoptionsstreaming chartslast pricenasdaq closing price as of pm et todays changebid size ask size day low  high  volume msellbuysnapshotchartsnewsoptionsearningsfundamentalsfinancialsinsiders argos therapeutics appoints dr ralph snyderman and irackly mtibelishvily to the companys board of directorsback to args news share storyam et  globe newswiredurham nc dec   globe newswire  argos therapeutics inc nasdaq args argos an immunooncology company focused on the development and commercialization of individualized immunotherapies based on the arcelis® precision immunotherapy technology platform today announced the appointment of ralph snyderman md and irackly mtibelishvily llm to the companys board of directors it is a privilege to welcome a pair of profoundly accomplished professionals to the argos board of directors who offer renowned expertise in each of their respective fields said jeff abbey president and ceo of argos dr snyderman is widely referred to as the ‘father of personalized medicine and his experience running the duke university health system as well as his senior leadership roles at genentech will help guide us as we advance our individualized immunotherapy through the final stages of clinical development assess indication expansion and approach our goal of becoming a fullyintegrated commercial company in addition irackly mtibelishvily is globally recognized as one of the most experienced international investment bankers and will advise on important corporate finance and other strategic activities in the years ahead dr snyderman is chancellor emeritus at duke university james b duke professor of medicine and director of the center for research on personalized health care  he served as chancellor for health affairs and dean of the duke university school of medicine from  to   during this time he oversaw the development of the duke university health system and served as its first president and chief executive officer dr snyderman has played a leading role in the conception and development of personalized health care an evolving model of national health care delivery  previously dr snyderman served as senior vice president for medical research and development at genentech inc the pioneering biomedical technology firm  he has played a leadership role in important national organizations such as the association of american physicians the national academy of medicine and association of american medical colleges dr snyderman earned a doctor of medicine degree from suny downstate medical center mr mtibelishvily is currently managing director and chairman of corporate and investment banking in central and eastern europe the middle east and africa for citigroup where he has served in various roles for nearly two decades a specialist in corporate finance capital markets securities and mergers and acquisitions mr mtibelishvily also has experience working with the multinational law firm clifford chance llp he earned a master of international legal studies degree from the moscow state institute of international relations and a master of laws degree from the university of virginia law school dr snyderman and mr mtibelishvily will replace vacating argos directors philippe van holle mba and andrei petrov phd on behalf of the management team board of directors and shareholders i would like to thank philippe and andrei for their dedication and support over the last several years said hubert birner phd chairman of the argos board of directors they each have played an instrumental role in the growth and development of argos about the arcelis® technology platformarcelis® is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patients individual disease it is designed to overcome immunosuppression by producing a specifically targeted durable memory tcell response without adjuvants that may be associated with toxicity the technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies the arcelis® process uses only a small disease sample or biopsy as the source of diseasespecific antigens and the patients own dendritic cells which are optimized from cells collected by a single leukapheresis procedure the proprietary process uses rna isolated from the patients disease sample to program dendritic cells to target diseasespecific antigens these activated antigenloaded dendritic cells are then formulated with the patients plasma and administered via intradermal injection as an individualized immunotherapy about argos therapeuticsargos therapeutics is an immunooncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its arcelis® technology platform argos most advanced product candidate ags is being evaluated in the pivotal adapt phase  clinical trial for the treatment of metastatic renal cell carcinoma mrcc  in addition ags is being studied in phase  investigatorinitiated clinical trials as neoadjuvant therapy for renal cell carcinoma rcc and for the treatment of nonsmall cell lung cancer nsclc argos is also developing a separate arcelis®based product candidate ags for the treatment of human immunodeficiency virus hiv which is currently being evaluated in an investigatorinitiated phase  clinical trial aimed at hiv eradication in adult patients forward looking statementsany statements in this press release about argos future expectations plans and prospects including statements about the expected and potential future closings of the private placement argos financial prospects anticipated use of proceeds future operations and sufficiency of funds for future operations clinical development of argos product candidates expectations regarding future clinical trials and future expectations and plans and prospects for argos and other statements containing the words believes anticipates estimates expects intends plans predicts projects targets may potential will would could should continue and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of   actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including whether argos cash resources will be sufficient to fund its continuing operations for the periods anticipated whether results obtained in clinical trials will be indicative of results obtained in future clinical trials whether argos product candidates will advance through the clinical trial process on a timely basis whether the results of such trials will warrant submission for approval from the united states food and drug administration or equivalent foreign regulatory agencies whether argos product candidates will receive approval from regulatory agencies on a timely basis or at all whether if product candidates obtain approval they will be successfully distributed and marketed and other factors discussed in the risk factors section of argos form q for the quarter ended september   which is on file with the sec and in other filings argos makes with the sec from time to time in addition the forwardlooking statements included in this press release represent argos views as of the date hereof argos anticipates that subsequent events and developments will cause argos views to change however while argos may elect to update these forwardlooking statements at some point in the future argos specifically disclaims any obligation to do so these forwardlooking statements should not be relied upon as representing argos views as of any date subsequent to the date hereofmedia contact adam daley berry  company public relations  adaleyberryprcom investor contact john menditto argos therapeutics inc  jmendittoargostherapeuticscom other top stories argsresults of elementia as of the second quarter church of scientology celebrates freedom of religiointellipharmaceutics provides update on fda advisoryxenith bankshares inc reports second quarter and fpulse seismic inc reports q  results most popular storiesargos therapeutics announces  secured convargos provides update on its adapt trial following margos therapeutics reports highlights from investor argos therapeutics reports first quarter  financdeadline alert brower piven alerts shareholders of most popular keyword searchestsla baba f twtr bac fb nflx aapl spy enter symbol or name gpro amd znga ddd jcp mjna amzn kkd goog fnma   argos therapeutics appoints dr ralph snyderman and irackly mtibelishvily to the company’s board of directors support   newswire  home  log in boards stocks commodities forex cryptocurrency the lounge hot breakout boards ihub my stocks activity ticker buzz cloud most read most posted most followed members recent news active boards site stats new boards cannabis stocks tools data tools  charts trader alerts trades portfolio top lists price  news alerts commodities markets in d newswire more tools  newsletters my image gallery advanced search videos all news stock screener news filter live charts live news live desktop forex prices commodities etf center educational channel personal finance qa streamer level  follow feed quotechartlevel tradesnewshistoricaltechnical analysismessage boardargos therapeutics inc mm nasdaq argos therapeutics appoints dr ralph snyderman and irackly mtibelishvily to the company’s board of directors date    am source  globenewswire inc stock  argos therapeutics inc mm args quote       pm argos therapeutics appoints dr ralph snyderman and irackly mtibelishvily to the company’s board of directorstweet print argos therapeutics inc nasdaqargshistorical stock chart  year  from jul  to jul  argos therapeutics inc nasdaqargs “argos” an immunooncology company focused on the development and commercialization of individualized immunotherapies based on the arcelis® precision immunotherapy technology platform today announced the appointment of ralph snyderman md and irackly mtibelishvily llm to the companys board of directors “it is a privilege to welcome a pair of profoundly accomplished professionals to the argos board of directors who offer renowned expertise in each of their respective fields” said jeff abbey president and ceo of argos “dr snyderman is widely referred to as the ‘father of personalized medicine’ and his experience running the duke university health system as well as his senior leadership roles at genentech will help guide us as we advance our individualized immunotherapy through the final stages of clinical development assess indication expansion and approach our goal of becoming a fullyintegrated commercial company in addition irackly mtibelishvily is globally recognized as one of the most experienced international investment bankers and will advise on important corporate finance and other strategic activities in the years ahead” dr snyderman is chancellor emeritus at duke university james b duke professor of medicine and director of the center for research on personalized health care  he served as chancellor for health affairs and dean of the duke university school of medicine from  to   during this time he oversaw the development of the duke university health system and served as its first president and chief executive officer dr snyderman has played a leading role in the conception and development of personalized health care an evolving model of national health care delivery  previously dr snyderman served as senior vice president for medical research and development at genentech inc the pioneering biomedical technology firm  he has played a leadership role in important national organizations such as the association of american physicians the national academy of medicine and association of american medical colleges dr snyderman earned a doctor of medicine degree from suny downstate medical center mr mtibelishvily is currently managing director and chairman of corporate and investment banking in central and eastern europe the middle east and africa for citigroup where he has served in various roles for nearly two decades a specialist in corporate finance capital markets securities and mergers and acquisitions mr mtibelishvily also has experience working with the multinational law firm clifford chance llp he earned a master of international legal studies degree from the moscow state institute of international relations and a master of laws degree from the university of virginia law school dr snyderman and mr mtibelishvily will replace vacating argos directors philippe van holle mba and andrei petrov phd “on behalf of the management team board of directors and shareholders i would like to thank philippe and andrei for their dedication and support over the last several years” said hubert birner phd chairman of the argos board of directors “they each have played an instrumental role in the growth and development of argos” about the arcelis® technology platformarcelis® is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient’s individual disease it is designed to overcome immunosuppression by producing a specifically targeted durable memory tcell response without adjuvants that may be associated with toxicity the technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies the arcelis® process uses only a small disease sample or biopsy as the source of diseasespecific antigens and the patient’s own dendritic cells which are optimized from cells collected by a single leukapheresis procedure the proprietary process uses rna isolated from the patients disease sample to program dendritic cells to target diseasespecific antigens these activated antigenloaded dendritic cells are then formulated with the patient’s plasma and administered via intradermal injection as an individualized immunotherapy about argos therapeuticsargos therapeutics is an immunooncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its arcelis® technology platform argos most advanced product candidate ags is being evaluated in the pivotal adapt phase  clinical trial for the treatment of metastatic renal cell carcinoma mrcc  in addition ags is being studied in phase  investigatorinitiated clinical trials as neoadjuvant therapy for renal cell carcinoma rcc and for the treatment of nonsmall cell lung cancer nsclc argos is also developing a separate arcelis®based product candidate ags for the treatment of human immunodeficiency virus hiv which is currently being evaluated in an investigatorinitiated phase  clinical trial aimed at hiv eradication in adult patients forward looking statementsany statements in this press release about argos’ future expectations plans and prospects including statements about the expected and potential future closings of the private placement argos’ financial prospects anticipated use of proceeds future operations and sufficiency of funds for future operations clinical development of argos’ product candidates expectations regarding future clinical trials and future expectations and plans and prospects for argos and other statements containing the words believes anticipates estimates expects intends plans predicts projects targets “may” potential will would could should continue and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of   actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including whether argos cash resources will be sufficient to fund its continuing operations for the periods anticipated whether results obtained in clinical trials will be indicative of results obtained in future clinical trials whether argos product candidates will advance through the clinical trial process on a timely basis whether the results of such trials will warrant submission for approval from the united states food and drug administration or equivalent foreign regulatory agencies whether argos product candidates will receive approval from regulatory agencies on a timely basis or at all whether if product candidates obtain approval they will be successfully distributed and marketed and other factors discussed in the risk factors section of argos’ form q for the quarter ended september   which is on file with the sec and in other filings argos makes with the sec from time to time in addition the forwardlooking statements included in this press release represent argos’ views as of the date hereof argos anticipates that subsequent events and developments will cause argos’ views to change however while argos may elect to update these forwardlooking statements at some point in the future argos specifically disclaims any obligation to do so these forwardlooking statements should not be relied upon as representing argos’ views as of any date subsequent to the date hereof media contact adam daley berry  company public relations  adaleyberryprcom investor contact john menditto argos therapeutics inc  jmendittoargostherapeuticscom latest args messages view more posts remove from favorites add to favorites  message board see more message board posts your recent history lse gkp gulf keyst lse qpp quindell ftse ukx ftse  lse iof iofina fx gbpusd uk sterlin stocks youve viewed will appear in this box letting you easily return to quotes youve seen previouslyregister now to create your own custom streaming stock watchlist nyse amex and asx quotes are delayed by at least  minutesall other quotes are delayed by at least  minutes unless otherwise stated citigroup hires new head of russia banking creates cis roles please be advised that this site is not optimized for use with microsoft internet explorer  for immediate release citigroup inc nyse c april   citigroup hires new head of russia banking creates cis roles moscow  citigroup has hired dmitry ankudinov as head of banking for russia one of the groups key focus countries within emea ankudinov joins from renaissance capital where he worked for more than  years most recently as a senior banker with coverage responsibility for some of the firms largest clients he supported activity across a number of businesses including investment banking asset management and consumer credit in conjunction with ankudinovs appointment citi has realigned its coverage model for the russiacommonwealth of independent states cis region irackly mtibelishvily currently chairman of russia banking will undertake additional responsibilities and become chairman of russiacis banking including kazakhstan and ukraine alex waechter currently head of banking for russia has been promoted to head of banking for cis reporting to irackly mtibelishvily the cis regional approach aligns the banking organization with citis other institutional businesses allowing a more integrated and effective delivery of advice products and client coverage says james bardrick cohead of banking emea this reorganization as well as dmitrys established track record in ma and capital markets origination coupled with his strong client relationships in the region will be key in taking the russian investment banking business forward more ways to get citi news get the app for android get the app for ios get email alerts citi citi the leading global financial services company has approximately  million customer accounts and does business in more than  countries and jurisdictions through citicorp and citi holdings citi provides consumers corporations governments and institutions with a broad range of financial products and services including consumer banking and credit corporate and investment banking securities brokerage transaction services and wealth management additional information may be found at wwwcitigroupcom